Loading...
XSHE
002020
Market cap1.74bUSD
Jul 10, Last price  
14.32CNY
1D
4.45%
1Q
-9.99%
Jan 2017
51.80%
IPO
587.36%
Name

Zhejiang Jingxin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002020 chart
P/E
16.27
P/S
3.03
EPS
0.88
Div Yield, %
2.55%
Shrs. gr., 5y
0.81%
Rev. gr., 5y
4.55%
Revenues
4.07b
-2.14%
432,592,479565,217,329510,305,555531,474,251631,018,882709,730,813857,582,262974,427,3751,235,496,1451,415,696,3551,875,460,9142,219,065,9702,943,801,9943,646,683,9053,258,075,4813,466,550,1553,779,846,2843,998,835,2194,158,550,6724,069,361,419
Net income
758m
+6.46%
14,031,1761,503,806-17,729,7603,752,63212,895,45829,119,50831,679,04364,348,192107,080,366166,044,368199,750,863264,376,954369,281,603520,396,187653,070,211612,541,767662,253,825618,898,036711,961,466757,979,439
CFO
781m
+7.60%
0029,983,689135,379,70659,548,10469,412,86860,276,649111,031,750210,488,270144,692,818252,694,495385,007,181523,403,340535,301,257513,210,535365,024,284855,777,798824,691,928726,161,370781,347,072
Dividend
May 29, 20250.35 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Jingxin Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the full spectrum of pharmaceutical activities, from research and development to manufacturing and sales within the country. Its diverse product line includes active pharmaceutical ingredients (APIs), along with a wide array of finished medications such as antihypertensives, various antibiotics (including quinolones and cephalosporins), gastrointestinal remedies, antidiabetics, antipileptics, antihistamines, H+ pump inhibitors, H2 receptor blockers, cholesterol-lowering drugs, and antidepressants, as well as biopharmaceutical products. Additionally, the company is a provider of advanced medical display solutions, offering diagnostic, surgical, clinical, large-screen, integrated, and ultrasonic medical displays. Originally founded in 1974 as Zhejiang Jingxin Pharmaceutical Factory, the company officially rebranded to Zhejiang Jingxin Pharmaceutical Co., Ltd. in 2000 and maintains its headquarters in Xinchang, China.
IPO date
Jul 15, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT